4 completed, 1 recruiting. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Recruiting 1 |
| Phase 2 | 2 | Completed 2 |
Follow Dragonfly Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety of Increasing Doses of DF5112 in Healthy Adults DF5112, Placebo - Healthy Participants, Healthy Adult Females | Phase 1 | Recruiting | Dragonfly Therapeutics | 48 | 2026-01-12 | 2026-04-01 |
| Study of DF6215 in Patients With Advanced Solid Tumors DF6215, pembrolizumab, KEYTRUDA® - Solid Tumor, Adult, Solid Tumor Cancer | Phase 1 | Completed | Dragonfly Therapeutics | 35 | 2023-11-28 | 2026-03-18 |
| Study of DF9001 in Patients With Advanced Solid Tumors DF9001, KEYTRUDA® (pembrolizumab) - Solid Tumor, Adult | Phase 1 / Phase 2 | Completed | Dragonfly Therapeutics | 24 | 2022-11-15 | 2025-10-29 |
| A Study of DF6002 Alone and in Combination With Nivolumab DF6002, Nivolumab - Solid Tumors | Phase 1 | Completed | Dragonfly Therapeutics | 170 | 2020-07-13 | 2026-03-18 |
| Study of DF1001 in Patients With Advanced Solid Tumors DF1001, Nivolumab, Nab paclitaxel - Solid Tumor, Adult | Phase 1 / Phase 2 | Completed | Dragonfly Therapeutics | 270 | 2019-11-11 | 2026-03-18 |
Carcinoma, Non-Small-Cell Lung (4) · Carcinoma, Renal Cell (2) · Melanoma (2) · Breast Neoplasms (1) · Head and Neck Neoplasms (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Nivolumab (2) · pembrolizumab (2) · Taxes (1)
United States (4) · Australia (3) · France (3) · Belgium (1) · Denmark (1) · Netherlands (1) · South Korea (1) · Spain (1)
2023 (1)